RxDoctor Payments Data

Jason Wagner, MD

Vascular Surgery · Sarasota, FLNPI 1902168925

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (44.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Merit Medical Systems Inc at 50.8% of the total. Among vascular surgery clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$62,212in general payments, 2019–2025

Across 401 payments — averaging $155.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merit Medical Systems Inc$32K
  • W. L. Gore & Associates, Inc.$7K
  • Penumbra, Inc.$5K
  • Medtronic$4K
  • Cook Medical LLC$3K
  • Abbott$2K
  • plus $9K from 32 others
$55,733in research payments, 2019–2025

Across 10 payments — averaging $5573.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merit Medical Systems Inc$56K

What the payments were for

  • Consulting fees$27,40344%
  • Speaking & faculty fees$2,6004%
  • Grants$1,0002%
  • Travel & lodging$8,37313%
  • Food & beverage$20,41133%
  • Other$2,4244%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,212 in reported general payments places this provider in the 90th percentile of 385 vascular surgery providers in Florida.

See all vascular surgery providers in Florida

Medicare billing

Part B allowed, 2024
$1,028,520
Medicare patients
986
Services billed
9,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$37,131
XareltoRivaroxaban15$15,181
ClopidogrelClopidogrel Bisulfate149$1,248
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen80$350
Tramadol Hcl46$109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$33$37,13143 claims
Johnson & JohnsonXarelto$210$15,18115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 385 vascular surgery providers in Florida.

Other vascular surgery in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →